Answers are grounded in this paper and cite their sources.
Clinical analysis reports uncertain chronic kidney disease risk in metabolic dysfunction-associated steatotic liver disease, highlighting unresolved questions regarding hepatic steatosis remission.
The association of the severity of hepatic steatosis in metabolic dysfunction-associated fatty liver disease (MAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) and the remission of MAFLD/MASLD with CKD occurrence is unclear.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: